Oncology News | pharmaphorum

News

Pharma M&A rumour mill grinds out Mirati's name again

Mirati Therapeutics is the subject of takeover speculation in the biopharma sector once again, as it waits for the FDA's decision on its KRAS

News

Opdivo backed by NICE for rare gastro-oesophageal cancers

Bristol-Myers Squibb's Opdivo has been recommended as a treatment for around 3,000 people with rare forms of gastro-oesophageal cancer via the NHS in England and Wales.

News

EC approves Regeneron's Libtayo for advanced cervical cancer

Regeneron has announced that the European Commission (EC) has approved Libtayo (cemiplimab) as a monotherapy for the treatment of adult patients with second-line recurrent or metastatic cer

News

Merck pledges revamp of R&D to drive productivity

Germany's Merck KGaA has said it needs to double the productivity of its R&D operations, with the aim of launching a new product every 18 months on average, to boost its pharma business

News

GSK will pull Blenrep from US market after failed trial

GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US

News

FogPharma clears another big-ticket financing for its 'minip...

Cambridge, Massachusetts-based FogPharma has closed another impressive fundraising round, adding $178 million to the pot as it ushers its polypeptide-based drug candidates towards the clini

Pharma M&A rumour mill grinds out Mirati's name again

Opdivo backed by NICE for rare gastro-oesophageal cancers

EC approves Regeneron's Libtayo for advanced cervical cancer

Merck pledges revamp of R&D to drive productivity

GSK will pull Blenrep from US market after failed trial

FogPharma clears another big-ticket financing for its 'minip...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks